<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Andreas Jung</style></author><author><style face="normal" font="default" size="100%">Annalisa Orenti</style></author><author><style face="normal" font="default" size="100%">Fiona Dunlevy</style></author><author><style face="normal" font="default" size="100%">Elina Aleksejeva</style></author><author><style face="normal" font="default" size="100%">Egil Bakkeheim</style></author><author><style face="normal" font="default" size="100%">Vladimir Bobrovnichy</style></author><author><style face="normal" font="default" size="100%">Siobhán B Carr</style></author><author><style face="normal" font="default" size="100%">Colombo, Carla</style></author><author><style face="normal" font="default" size="100%">Harriet Corvol</style></author><author><style face="normal" font="default" size="100%">Rebecca Cosgriff</style></author><author><style face="normal" font="default" size="100%">Géraldine Daneau</style></author><author><style face="normal" font="default" size="100%">Deniz Dogru</style></author><author><style face="normal" font="default" size="100%">Pavel Drevinek</style></author><author><style face="normal" font="default" size="100%">Vukic, Andrea Dugac</style></author><author><style face="normal" font="default" size="100%">Isabelle Fajac</style></author><author><style face="normal" font="default" size="100%">Alice Fox</style></author><author><style face="normal" font="default" size="100%">Stojka Fustik</style></author><author><style face="normal" font="default" size="100%">Gulmans, Vincent</style></author><author><style face="normal" font="default" size="100%">Harutyunyan, Satenik</style></author><author><style face="normal" font="default" size="100%">Hatziagorou, Elpis</style></author><author><style face="normal" font="default" size="100%">Irena Kasmi</style></author><author><style face="normal" font="default" size="100%">Hana Kayserová</style></author><author><style face="normal" font="default" size="100%">Elena Kondratyeva</style></author><author><style face="normal" font="default" size="100%">Uroš Krivec</style></author><author><style face="normal" font="default" size="100%">Halyna Makukh</style></author><author><style face="normal" font="default" size="100%">Malakauskas, Kestutis</style></author><author><style face="normal" font="default" size="100%">Edward F McKone</style></author><author><style face="normal" font="default" size="100%">Mei-Zahav, Meir</style></author><author><style face="normal" font="default" size="100%">de Monestrol, Isabelle</style></author><author><style face="normal" font="default" size="100%">Hanne Vebert Olesen</style></author><author><style face="normal" font="default" size="100%">Rita Padoan</style></author><author><style face="normal" font="default" size="100%">Tsitsino Parulava</style></author><author><style face="normal" font="default" size="100%">Maria Dolores Pastor-Vivero</style></author><author><style face="normal" font="default" size="100%">Luísa Pereira</style></author><author><style face="normal" font="default" size="100%">Guergana Petrova</style></author><author><style face="normal" font="default" size="100%">Andreas Pfleger</style></author><author><style face="normal" font="default" size="100%">Liviu Pop</style></author><author><style face="normal" font="default" size="100%">Jacqui G van Rens</style></author><author><style face="normal" font="default" size="100%">Milan Rodic</style></author><author><style face="normal" font="default" size="100%">Marc Schlesser</style></author><author><style face="normal" font="default" size="100%">Valérie Storms</style></author><author><style face="normal" font="default" size="100%">Oxana Turcu</style></author><author><style face="normal" font="default" size="100%">Lukasz Woz Niacki</style></author><author><style face="normal" font="default" size="100%">Panayiotis Yiallouros</style></author><author><style face="normal" font="default" size="100%">Zolin, Anna</style></author><author><style face="normal" font="default" size="100%">Damian G Downey</style></author><author><style face="normal" font="default" size="100%">Naehrlich, Lutz</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe.</style></title><secondary-title><style face="normal" font="default" size="100%">ERJ Open Res</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Oct</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">7</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in people with cystic fibrosis (pwCF) can lead to severe outcomes.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;In this observational study, the European Cystic Fibrosis Society Patient Registry collected data on pwCF and SARS-CoV-2 infection to estimate incidence, describe clinical presentation and investigate factors associated with severe outcomes using multivariable analysis.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Up to December 31, 2020, 26 countries reported information on 828 pwCF and SARS-CoV-2 infection. Incidence was 17.2 per 1000 pwCF (95% CI: 16.0-18.4). Median age was 24 years, 48.4% were male and 9.4% had lung transplants. SARS-CoV-2 incidence was higher in lung-transplanted (28.6; 95% CI: 22.7-35.5) non-lung-transplanted pwCF (16.6; 95% CI: 15.4-17.8) (p≤0.001).SARS-CoV-2 infection caused symptomatic illness in 75.7%. Factors associated with symptomatic SARS-CoV-2 infection were age &amp;gt;40 years, at least one F508del mutation and pancreatic insufficiency.Overall, 23.7% of pwCF were admitted to hospital, 2.5% of those to intensive care, and regretfully 11 (1.4%) died. Hospitalisation, oxygen therapy, intensive care, respiratory support and death were 2- to 6-fold more frequent in lung-transplanted non-lung-transplanted pwCF.Factors associated with hospitalisation and oxygen therapy were lung transplantation, cystic fibrosis-related diabetes (CFRD), moderate or severe lung disease and azithromycin use (often considered a surrogate marker for infection and poorer lung function).&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSION: &lt;/b&gt;SARS-CoV-2 infection yielded high morbidity and hospitalisation in pwCF. PwCF with forced expiratory volume in 1 s &amp;lt;70% predicted, CFRD and those with lung transplants are at particular risk of more severe outcomes.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue></record></records></xml>